Ion Beam Applications SA (IBAB.BR)
5.54EUR
24 May 2013
€0.00 (+0.00%)
€5.54
€5.56
€5.59
€5.48
10,167
20,668
€7.12
€3.77
IBAB.BR
About
Overall
| Beta: | 1.32 |
| Market Cap (Mil.): | €152.00 |
| Shares Outstanding (Mil.): | 27.44 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| IBAB.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 78.87 | 34.30 |
| EPS (TTM): | -1.57 | -- | -- |
| ROI: | -17.74 | 4.12 | 18.43 |
| ROE: | -39.59 | 9.08 | 19.30 |
IBA agrees initial deal to sell drug discovery unit
BRUSSELS, May 14 - Belgian cancer diagnosis and therapy company Ion Beam Applications said on Tuesday it had provisionally agreed the sale of its drug discovery arm to a European private equity firm for 25 million euros ($32.5 million).
IBA Q1 revenues fall 14 percent as fails to covert orders
BRUSSELS, May 8 - Belgian cancer treatment company Ion Beam Applications said on Wednesday its first-quarter sales fell 13.9 percent as it signed fewer deals for its radiation therapy devices.
Fitch Rates IBA-Moscow's Bonds 'BB(EXP)'
(The following statement was released by the rating agency) LONDON/MOSCOW, March 27 (Fitch) Fitch Ratings has assigned Russia-based IBA-Moscow's (IBAM) upcoming RUB3bn bond issue an expected 'BB(EXP)' Long-term rating. The issue benefits from recourse to IBAM's parent, International Bank of Azerbaijan (IBA, 'BB'/Stable/'b-'). The bond will have a three-year tenor, and proceeds from the issue will be used solely for IBAM's purposes. Should IBAM fail to make an interest or principal payment u
IBA says on verge of settling German dispute
LOUVAIN-LA-NEUVE, Belgium, March 18 - Belgium's IBA SA said on Monday it had resolved a legal dispute over one of its proton therapy devices in the German city of Essen, which was partly responsible for its net loss last year.
Belgium's IBA sees revenue growth in 2013
BRUSSELS, March 18 - Belgium's IBA SA expects revenues to grow in the low single digits this year as it signs deals for eight to 12 rooms of its proton therapy devices, which deliver highly targeted radiotherapy treatment for cancer.
RPT-IBA signs 50 mln euros contract in India
(Repeats to additional subscribers without changes to text)
IBA signs 50 mln euros contract in India
BRUSSELS, Jan 21 - IBA, a Belgian radiology device maker, has signed an about 50 million euro ($66.46 million) contract to install the first ultra-precise proton therapy devices in India, the group said on Monday.
BRIEF-IBA signs $50 mln Texas contract
BRUSSELS, Dec 21 - Ion Beam Applications SA : * Says signs contract with Texas proton therapy center for a multi-room proton
Belgium's IBA announces $26.2 mln sale order
BRUSSELS, Dec 14 - Belgian cancer treatment equipment maker IBA said on Friday it has sold the first of its compact Proteus ONE radiology systems in Europe.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
